Small group, but not small enough that the results can simply be ignored by sufferers, the wider medical community, and regulatory bodies. Months and months of treatment and no side effects and an apparent delay of symptoms at worst. Sometimes, it beggars belief that a life extending treatment cannot be fast tracked and widened out to a community, where currently, there is only one horrible, short term outcome.
Ann: Final Ethics Approval for Open-Label MND Extension Study, page-9
-
- There are more pages in this discussion • 69 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.5¢ |
Change
0.010(6.06%) |
Mkt cap ! $87.51M | |||
| Open | High | Low | Value | Volume |
| 17.0¢ | 18.0¢ | 16.8¢ | $90.74K | 523.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 300788 | 17.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 354167 | 7 |
View Market Depth
| Last trade - 13.56pm 16/08/2024 (20 minute delay) ? |
| PAA (ASX) Chart |